Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages 4105-4114

  Spigel, David R ^a,b   Ervin, Thomas J ^a,d   Ramlau, Rodryg A ^f   Daniel, Davey B ^a,c   Goldschmidt, Jerome H ^h   Blumenschein, George R ⁱ   Krzakowski, Maciej J ^g   Robinet, Gilles ^j   Godbert, Benoit ^k   Barlesi, Fabrice ^l   Govindan, Ramaswamy ^m   Patel, Taral ⁿ   Orlov, Sergey V ^o   Wertheim, Michael S ^e   Yu, Wei ^p   Zha, Jiping ^r   Yauch, Robert L ^p   Patel, Premal H ^p   Phan, See Chun ^p   Peterson, Amy C ^q  

^a SARAH CANNON RESEARCH INSTITUTE   (United Kingdom)

^b Tennessee Oncology   (United States)

^c Chattanooga Oncology Hematology Associates   (United States)

^d Florida Cancer Specialists   (United States)

^e Hematology Oncology Associates   (United States)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h Christianburg   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j BREST UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

^m WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ Mid Ohio Oncology Hematology   (United States)

^o PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^p GENENTECH INC   (United States)

^q Medivation Inc   (United States)

^r rown Bioscience   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; MONOCLONAL ANTIBODY; ONARTUZUMAB; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR;

ADULT; AGED; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84890108571     PISSN: None     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/jco.2012.47.4189     Document Type: Article

References (0)